In November 2025, Citest Diagnostics launched the Digital Pregnancy Tests - a user-friendly and advanced diagnostic solution designed for the qualitative detection of human chorionic gonadotropin (hCG) in human urine samples. hCG, a hormone secreted by the placenta during pregnancy, is a key indicator of early pregnancy development and these digital tests leverage ultra-sensitive thresholds (25 mIU/mL or 10 mIU/mL) to enable early pregnancy detection.

These digital pregnancy tests stand out with their innovative design and functionality. As rapid and user-friendly devices, they feature a one-step operation for ease of use and deliver results in just 3 minutes, ensuring swift answers for users. The easy-to-read digital display presents clear results, combining convenience with efficiency in the pregnancy detection process.

The tests offer four core advantages: they enable early detection of pregnancy, supporting users in identifying pregnancy at its earliest stages; they are incredibly easy to use with a simple one-step operation, eliminating complexity; the digital display ensures results are easy to read and interpret; and they maintain high accuracy, providing reliable outcomes for users. Product offerings include the Digital hCG Pregnancy Test (Cat. No.: FHC-CTE103H, cut-off: 25 mIU/mL) and the Digital Early Pregnancy Test (Cat. No.: FHC-CTEU103H, cut-off: 10 mIU/mL), both utilizing urine specimens and available in packs of 1 test (1T).

In conclusion, Citest's Digital Pregnancy Tests redefine at-home pregnancy detection by integrating early detection capabilities, user-friendliness, clear readability and high accuracy. By addressing the need for reliable and timely pregnancy identification, these tests empower users with informed decisions during this pivotal life moment. Citest Diagnostics is committed to develop innovative, accessible diagnostic solutions that enhance personal health management and improve user experiences globally.